Masaomi Miyamoto

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. pmc Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders
    Masaomi Miyamoto
    Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, 4 1 1 Doshomachi, Chuo Ku, Osaka, Japan
    CNS Neurosci Ther 15:32-51. 2009
  2. ncbi The sleep-promoting action of ramelteon (TAK-375) in freely moving cats
    Masaomi Miyamoto
    Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    Sleep 27:1319-25. 2004
  3. ncbi [Drugs for insomnia and improving quality of life (QOL): research and development of ramelteon, an MT1/MT2-receptor agonist]
    Masaomi Miyamoto
    Nihon Yakurigaku Zasshi 131:16-21. 2008
  4. ncbi Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice
    Masaomi Miyamoto
    Pharmacology Research Laboratories III, Takeda Pharmaceutical Company Limited, Osaka 532 8686, Japan
    Neurosci Lett 402:201-4. 2006
  5. ncbi Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists
    Osamu Uchikawa
    Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 45:4222-39. 2002
  6. ncbi Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys
    Nobuhito Yukuhiro
    Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka 532 8686, Japan
    Brain Res 1027:59-66. 2004
  7. ncbi Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist
    Koki Kato
    Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka 532 8686, Japan
    Neuropharmacology 48:301-10. 2005
  8. ncbi Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists
    Kohji Fukatsu
    Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 45:4212-21. 2002
  9. ncbi Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats
    Keisuke Hirai
    Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    J Biol Rhythms 20:27-37. 2005
  10. ncbi [Recent and potential drugs for treatment of insomnia]
    Akira Terao
    Nihon Yakurigaku Zasshi 129:35-41. 2007

Collaborators

  • Osamu Uchikawa
  • H Fukumoto
  • Taisuke Tomita
  • Naoki Tarui
  • Akira Terao
  • T Iwatsubo
  • Keisuke Hirai
  • Shigenori Ohkawa
  • Koki Kato
  • Hideki Takahashi
  • Kohji Fukatsu
  • Hisao Nishikawa
  • Nobuhito Yukuhiro
  • Shuji Hinuma
  • Takahito Hara
  • Kaneyoshi Kato
  • Jun Terauchi
  • Ryouta Maeda
  • Hiroyuki Ohta
  • Keiji Nishiyama
  • Muneto Kita
  • Yuji Kawamata
  • Yuu Fujiwara
  • Hiroyuki Kimura
  • Shin ichi Yoshikubo
  • Jun ichi Miyazaki
  • Masami Kusaka
  • Naoyuki Kanzaki
  • Hideo Araki
  • Masuo Yamaoka
  • Toru Yamano
  • Masayuki Yamashita
  • Mitsuru Kawada

Detail Information

Publications13

  1. pmc Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders
    Masaomi Miyamoto
    Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, 4 1 1 Doshomachi, Chuo Ku, Osaka, Japan
    CNS Neurosci Ther 15:32-51. 2009
    ..Ramelteon has demonstrated sleep-promoting effects in clinical trials, and coupled with its favorable safety profile and lack of abuse potential or dependence, this chronohypnotic provides an important treatment option for insomnia...
  2. ncbi The sleep-promoting action of ramelteon (TAK-375) in freely moving cats
    Masaomi Miyamoto
    Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    Sleep 27:1319-25. 2004
    ..Ramelteon (TAK-375) is an MT1/MT2 receptor agonist being studied for the treatment of insomnia and circadian rhythm sleep disorders. We compared the behavioral effects of ramelteon and exogenous melatonin in freely moving cats...
  3. ncbi [Drugs for insomnia and improving quality of life (QOL): research and development of ramelteon, an MT1/MT2-receptor agonist]
    Masaomi Miyamoto
    Nihon Yakurigaku Zasshi 131:16-21. 2008
  4. ncbi Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice
    Masaomi Miyamoto
    Pharmacology Research Laboratories III, Takeda Pharmaceutical Company Limited, Osaka 532 8686, Japan
    Neurosci Lett 402:201-4. 2006
    ..o.), treatment with melatonin and N-acetyl-5-HT exacerbated the impairment by diazepam. Ramelteon had no significant effect on the diazepam-induced impairment of motor coordination...
  5. ncbi Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists
    Osamu Uchikawa
    Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 45:4222-39. 2002
    ..S)-(-)-22b (TAK-375) is currently under clinical trial for the treatment of insomnia and circadian rhythm disorders...
  6. ncbi Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys
    Nobuhito Yukuhiro
    Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka 532 8686, Japan
    Brain Res 1027:59-66. 2004
    ..The EEG power spectra of zolpidem were qualitatively different from that of naturally occurring physiological sleep. Results of the present study support the investigation of ramelteon as a sleep-promoting agent in humans...
  7. ncbi Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist
    Koki Kato
    Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka 532 8686, Japan
    Neuropharmacology 48:301-10. 2005
    ..Taken together, these results indicate that ramelteon is a potent and highly selective agonist of MT1/MT2 melatonin receptors...
  8. ncbi Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists
    Kohji Fukatsu
    Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 45:4212-21. 2002
    ..In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established...
  9. ncbi Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats
    Keisuke Hirai
    Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    J Biol Rhythms 20:27-37. 2005
    ....
  10. ncbi [Recent and potential drugs for treatment of insomnia]
    Akira Terao
    Nihon Yakurigaku Zasshi 129:35-41. 2007
  11. doi A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease
    Hiroaki Fukumoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Yodogawa ku, Osaka 532 8686, Japan
    J Neurosci 30:11157-66. 2010
    ..These results support the feasibility of BACE1 inhibition with a noncompetitive inhibitor as disease-modifying as well as symptomatic therapy for AD...
  12. doi Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on Aβ peptide levels and impaired learning behavior in aged rats
    Hideki Takahashi
    Pharmacology Research Laboratories, Takeda Pharmaceutical Company Limited, 17 85 Juso honmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    Brain Res 1361:146-56. 2010
    ..Our findings support the idea that partial inhibition of BACE1 by TAK-070 exerts symptomatic as well as disease-modifying effects for the treatment of Alzheimer's disease...
  13. ncbi Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome
    Takahito Hara
    Pharmaceutical Research Laboratories, Takeda Chemical Industries, Ltd, Osaka 532 8686, Japan
    Cancer Res 63:149-53. 2003
    ..Our data strongly support the hypothesis that AR mutation is one possible mechanism of the AWS and suggest that flutamide might be effective as a second-line therapy for refractory PC previously treated with bicalutamide...